Company Overview

NextGen Group PLC (LSE:NGG) is a provider of protein biomarker services, biomarkerexpress™, for pharmaceutical and biotech companies globally, operating as NextGen Sciences.

NextGen Sciences' range of services, which include biomarker discovery, assay development and a testing laboratory, are employed by customers as a key part of the drug and diagnostic development process. NextGen uses advanced and proprietary techniques to develop accurate, precise and robust biomarker assays, which are used to test pre-clinical and clinical samples for drug efficacy and safety, and for the development of personalized treatment for patients.

As well as biomarker services, NextGen Sciences has a range of capabilities to offer clients, including protein identification, characterization, quantitation and proteome mapping, and an enviable record for providing high-quality fast results.

NextGen Sciences' management team has a track record of progressing technology solutions and delivering first-class services to market. The company has worked with 16 of the top 20 pharmaceutical companies resulting in several Master Service Agreements being placed.

NextGen Sciences continues to invest in cutting-edge technologies and form strategic alliances to offer the best quality and most comprehensive protein biomarker services to its pharmaceutical and biotech customers.